Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MBRX

Moleculin Biotech Inc

Dec 06 • 04:00PM ET

0.5706

Dollar change -0.0194
Percentage change -3.29	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.90	Insider Own	3.28%	Shs Outstand	29.81M	Perf Week	-0.77%
Market Cap	17.01M	Forward P/E	-	EPS next Y	-0.84	Insider Trans	0.00%	Shs Float	28.83M	Perf Month	-2.88%
Income	-26.27M	PEG	-	EPS next Q	-0.22	Inst Own	7.22%	Short Float / Ratio	1.03% / 1.88	Perf Quarter	46.12%
Sales	0.00M	P/S	-	EPS this Y	12.87%	Inst Trans	0.36%	Short Interest	0.30M	Perf Half Y	-12.82%
Book/sh	1.18	P/B	0.48	EPS next Y	4.92%	ROA	-50.09%	Target Price	9.50	Perf Year	-56.77%
Cash/sh	0.82	P/C	0.69	EPS next 5Y	-	ROE	-56.16%	52W Range	0.34 - 1.65	Perf YTD	-46.17%
Dividend	-	P/FCF	-	EPS past 5Y	20.36%	ROI	-73.72%	52W High	-65.42%	Beta	1.94
Dividend %	-	Quick Ratio	7.10	Sales past 5Y	0.00%	Gross Margin	-	52W Low	68.97%	ATR	0.05
Employees	19	Current Ratio	7.10	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	52.49	Volatility	5.98% 9.90%
Optionable	No	Debt/Eq	0.02	EPS Q/Q	37.43%	Profit Margin	-	Rel Volume	0.32	Prev Close	0.59
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Nov 13 BMO	Payout	-	Avg Volume	157.58K	Price	0.57
Recom	1.00	SMA20	0.48%	SMA50	10.34%	SMA200	-14.78%	Volume	53,606	Change	-3.29%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-22	Resumed	Oppenheimer	Outperform	$14

Nov-14-23 01:46PM	Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:29AM	Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies (Zacks)
Nov-13-23 08:05AM	Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months (PR Newswire) +6.70%
08:00AM	Moleculin Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-07-23 08:45AM	Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast (PR Newswire) -5.53%
08:35AM	Loading…
Nov-06-23 08:35AM	Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases (PR Newswire) +14.97%
Oct-24-23 07:45AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -5.91%
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE)
Oct-11-23 09:05AM	Moleculin to Participate in the Virtual Investor Ask the CEO Conference (PR Newswire) +5.58%
Oct-02-23 08:40AM	Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) (PR Newswire)
Sep-22-23 07:58AM	Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up (Zacks) -7.14%
Sep-21-23 08:50AM	Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107) (PR Newswire) +9.95%
Sep-18-23 08:40AM	Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin (PR Newswire)
Sep-14-23 08:35AM	Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting (PR Newswire)
Sep-05-23 08:35AM	Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
12:16AM	Loading…
Aug-12-23 12:16AM	Q2 2023 Moleculin Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-11-23 06:45AM	Moleculin Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-10-23 04:05PM	Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones (PR Newswire)
Aug-07-23 08:40AM	Moleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling (PR Newswire)
Aug-03-23 08:45AM	Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast (PR Newswire)
Jul-13-23 08:40AM	Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) (PR Newswire) +17.72%
Jul-06-23 08:45AM	Moleculin to Participate in the Virtual Investor Summer Spotlight Series (PR Newswire)
Jun-13-23 08:35AM	Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (PR Newswire)
May-30-23 09:05AM	Moleculin Announces Adjournment of 2023 Annual Meeting to June 15, 2023 (PR Newswire) +7.72%
May-12-23 11:15AM	Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2023 Earnings Call Transcript (Insider Monkey) -11.26%
May-11-23 08:04AM	MBRX Stock Earnings: Moleculin Biotech Misses EPS Estimates (InvestorPlace)
07:05AM	Moleculin Reports First Quarter 2023 Financial Results (PR Newswire)
May-10-23 04:05PM	Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones (PR Newswire)
May-04-23 08:35AM	Moleculin to Report First Quarter Financial Results on May 11, 2023 and Host Conference Call and Webcast (PR Newswire)
May-02-23 08:35AM	Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) (PR Newswire)
09:55AM	Loading…
Apr-24-23 09:55AM	Here's Why Moleculin Biotech, Inc. (MBRX) Looks Ripe for Bottom Fishing (Zacks)
Apr-18-23 05:33PM	What's Going On With Moleculin Biotech Stock Today? (Benzinga) -8.34%
01:35PM	Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models (PR Newswire)
Mar-27-23 12:00PM	Moleculin Biotech, Inc. (MBRX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
06:26AM	Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 05:33AM	Q4 2022 Moleculin Biotech Inc Earnings Call (Thomson Reuters StreetEvents) +7.09%
Mar-23-23 07:10AM	Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update (PR Newswire) -8.44%
Mar-22-23 04:20PM	Moleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials (PR Newswire) +5.10%
Mar-21-23 08:50AM	Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 (PR Newswire)
Mar-15-23 08:30AM	Moleculin to Report Full Year 2022 Financial Results on March 22, 2023 and Host Conference Call and Webcast (PR Newswire)
Mar-13-23 08:35AM	Moleculin to Present at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire) -6.23%
07:05AM	Moleculin Announces it Has No Exposure to Silicon Valley Bank Situation (PR Newswire)
Mar-09-23 08:35AM	Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer (PR Newswire)
Mar-01-23 08:45AM	Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) (PR Newswire)
Feb-13-23 11:30AM	Moleculin Reveals Final Topline Data From European Study Of Annamycin In Leukemia Setting (Benzinga)
08:10AM	Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) (PR Newswire)
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
Jan-05-23 08:45AM	Moleculin to Present at the Virtual Investor 2023 Companies to Watch Event (PR Newswire)
Dec-21-22 08:25AM	Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) (PR Newswire) -5.30%
Dec-19-22 09:15AM	Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-15-22 01:09PM	Moleculin Biotech's Annamycin In Leukemia Study Shows 80% Overall Response Rate (Benzinga)
08:35AM	Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML) (PR Newswire)
Dec-07-22 08:45AM	Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme (PR Newswire) +15.50%
Nov-14-22 05:23PM	Biotech firm Moleculin touts strong cash position, clinical trials in Q3 earnings call (American City Business Journals)
Nov-10-22 04:05PM	Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update (PR Newswire)
Nov-07-22 09:05AM	Moleculin to Report Third Quarter 2022 Financial Results on November 10, 2022 and Host Inaugural Quarterly Conference Call and Webcast (PR Newswire)
Oct-14-22 08:40AM	Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK (PR Newswire)
Sep-27-22 01:01PM	Moleculin Biotech's Potential Antiviral Compound Selected For NIAID-Funded Animal Studies (Benzinga)
08:35AM	Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral (PR Newswire)
Sep-23-22 09:11AM	Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event (PR Newswire)
Sep-08-22 08:45AM	Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (PR Newswire)
Sep-07-22 08:35AM	Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Sep-06-22 08:45AM	Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme (PR Newswire)
Aug-19-22 08:40AM	Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK (PR Newswire)
Aug-15-22 08:35AM	Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update (PR Newswire) +11.11%
Jul-28-22 08:35AM	Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (PR Newswire)
Jul-11-22 10:22AM	Companies Like Moleculin Biotech (NASDAQ:MBRX) Are In A Position To Invest In Growth (Simply Wall St.)
Jul-08-22 08:35AM	Moleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK (PR Newswire)
Jun-16-22 08:35AM	Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK (PR Newswire)
May-26-22 08:35AM	Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 (PR Newswire)
May-19-22 08:05AM	Moleculin to Present at the H.C. Wainwright Global Investment Conference (PR Newswire)
May-12-22 08:35AM	Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update (PR Newswire)
May-10-22 08:35AM	Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 (PR Newswire)
May-05-22 08:15AM	Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) (PR Newswire)
May-04-22 08:15AM	Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer (PR Newswire) -5.49%
Apr-21-22 08:47AM	Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma (PR Newswire)
Apr-14-22 08:05AM	Moleculin Announces Corporate Rebranding and Launch of New Website (PR Newswire)
Apr-11-22 07:05AM	/C O R R E C T I O N -- Moleculin Biotech, Inc./ (PR Newswire)
Apr-08-22 01:05PM	Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting (PR Newswire)
Mar-25-22 07:05AM	Moleculin Reports Full Year Financial Results and Provides Programs Update (PR Newswire)
Mar-23-22 08:05AM	Moleculin to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest (PR Newswire)
Mar-11-22 08:05AM	Moleculin to Present at the Oppenheimer 32nd Annual Healthcare Conference (PR Newswire)
Mar-01-22 08:35AM	Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors (PR Newswire)
Feb-14-22 02:10PM	Moleculin Biotech Annamycin Doublet Therapy Shows 68% Overall Survival In Animal Study (Benzinga)
09:05AM	Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development (PR Newswire)
Feb-01-22 09:11AM	Companies Like Moleculin Biotech (NASDAQ:MBRX) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-20-22 08:40AM	Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference (PR Newswire)
Jan-18-22 08:05AM	Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma (PR Newswire)
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th (ACCESSWIRE)
Jan-07-22 08:30AM	Moleculin to Present at the H.C. Wainwright BioConnect Conference (PR Newswire)
Dec-27-21 08:05AM	Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (PR Newswire) -8.87%
Dec-01-21 08:35AM	Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme (PR Newswire) +5.80%
Nov-12-21 08:05AM	Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event (PR Newswire)
Nov-11-21 08:05AM	Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update (PR Newswire)
Nov-04-21 02:30PM	JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th (ACCESSWIRE)
Oct-20-21 05:46PM	Houston biotech cos. begin clinical trials for cancer, Covid-19 treatments (American City Business Journals)
Oct-19-21 09:05AM	Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 (PR Newswire)
Oct-18-21 08:25AM	Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (PR Newswire)
Sep-27-21 07:05AM	Moleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference (PR Newswire)
Sep-17-21 08:05AM	Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit (PR Newswire) +5.42%

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MBRX

Moleculin Biotech Inc

Upgrade your FINVIZ experience